PRV-3279-2a Trial in Systemic Lupus

Summary

The PREVAIL-2 study was designed to assess the safety and potential efficacy of PRV-3279 in flare prevention in systemic lupus erythematosus (SLE) participants with active disease after amelioration induced by corticosteroid treatment.

Timeline

Start

2022-01-20

Primary completion

2024-05-14

Completion

2024-06-24

Drugs

Indications